Literature DB >> 21497736

The efficacy of anticonvulsants on orofacial pain: a systematic review.

Wilhelmus J J M Martin1, Tymour Forouzanfar.   

Abstract

OBJECTIVE: Controversy exists about the effectiveness of anticonvulsants for the management of orofacial pain disorders. To ascertain appropriate therapies, a systematic review was conducted of existing randomized controlled trials. STUDY
DESIGN: Trials were identified from PubMed, Cochrane, and Ovid Medline databases from 1962 through March 2010, from references in retrieved reports, and from references in review articles. Eight useful trials were identified for this review. Six studies were randomized placebo-controlled trials and 2 studies were randomized active-controlled. Two independent investigators reviewed these articles by using a 15-item checklist.
RESULTS: Four studies were classified as "high quality." However, heterogeneity of the trials and the small sample sizes precluded the drawing of firm conclusions about the efficacy of the interventions studied on orofacial pain patients.
CONCLUSIONS: There is limited to moderate evidence supporting the efficacy of commonly used anticonvulsants for treatment of patients with orofacial pain disorders. More randomized controlled trials are needed on the efficacy of anticonvulsants.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21497736     DOI: 10.1016/j.tripleo.2011.01.033

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  9 in total

Review 1.  Clonazepam for neuropathic pain and fibromyalgia in adults.

Authors:  Ruth Corrigan; Sheena Derry; Philip J Wiffen; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Effectiveness of Curcumin in Reducing Self-Rated Pain-Levels in the Orofacial Region: A Systematic Review of Randomized-Controlled Trials.

Authors:  Barbara Sterniczuk; Paul Emile Rossouw; Dimitrios Michelogiannakis; Fawad Javed
Journal:  Int J Environ Res Public Health       Date:  2022-05-25       Impact factor: 4.614

3.  Facial pain followed by unilateral facial nerve palsy: a case report with literature review.

Authors:  Sowmya Gv; Manjunatha Bs; Saurabh Goel; Mohit Pal Singh; Madhusudan Astekar
Journal:  J Clin Diagn Res       Date:  2014-08-20

4.  Current evidence on atypical odontalgia: diagnosis and clinical management.

Authors:  Yoshihiro Abiko; Hirofumi Matsuoka; Itsuo Chiba; Akira Toyofuku
Journal:  Int J Dent       Date:  2012-07-09

Review 5.  Efficacy of medications in adult patients with trigeminal neuralgia compared to placebo intervention: a systematic review with meta-analyses.

Authors:  Georgia M Peterson-Houle; Magda R AbdelFattah; Mariela Padilla; Reyes Enciso
Journal:  J Dent Anesth Pain Med       Date:  2021-10-01

Review 6.  Orofacial pain management: current perspectives.

Authors:  Marcela Romero-Reyes; James M Uyanik
Journal:  J Pain Res       Date:  2014-02-21       Impact factor: 3.133

7.  Effects of Kamishoyosan, a Traditional Japanese Kampo Medicine, on Pain Conditions in Patients with Intractable Persistent Dentoalveolar Pain Disorder.

Authors:  Young-Chang P Arai; Izumi Makino; Shuichi Aono; Hiromichi Yasui; Hideya Isai; Makoto Nishihara; Noboru Hatakeyama; Takashi Kawai; Tatsunori Ikemoto; Shinsuke Inoue; Takahiro Ushida
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-01       Impact factor: 2.629

8.  Jaw Exercise Therapy and Psychoeducation to Reduce Oral Parafunctional Activities for the Management of Persistent Dentoalveolar Pain.

Authors:  Izumi Makino; Young-Chang Arai; Shuichi Aono; Masayuki Inoue; Hiroki Sakurai; Yusuke Ohmichi; Kazuhiro Shimo; Makoto Nishihara; Jun Sato; Noboru Hatakeyama; Takako Matsubara; Tatsunori Ikemoto; Takahiro Ushida
Journal:  Pain Res Manag       Date:  2018-09-12       Impact factor: 3.037

Review 9.  Limited Utility for Benzodiazepines in Chronic Pain Management: A Narrative Review.

Authors:  Steven L Wright
Journal:  Adv Ther       Date:  2020-05-06       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.